Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

For those wanting the home test kit, free rapid antigen tests will continue to be available through local public health units ...

the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine, including the Omicron JN.1-adapted (including the KP.2 strain of the SARS-CoV-2 Omicron JN.1 sublineage) monovalent COVID ...

Covid-19 vaccines are available across the United States. Vaccines represent the best protection against sever illness and ...

mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025 NEW YORK ...

Gov. Ron DeSantis’ controversial surgeon general continues to advise against mRNA COVID-19 vaccines. The newest vaccine is ...

1 sublineages, including KP.2, KP.3 and LB.1, compared with the companies’ Omicron XBB.1.5 adapted Covid-19 vaccine .3 The Covid-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary ...